Curated News
By: NewsRamp Editorial Staff
May 13, 2026

Kairos Pharma CEO to Present at LD Micro Invitational

View History of this news story on GitHub
Original Source

TLDR

  • Kairos Pharma CEO presents at LD Micro, showcasing ENV-105's potential to overcome drug resistance and gain market edge.
  • Kairos Pharma's ENV-105 targets CD105 to reverse drug resistance, now in Phase 2 for prostate and Phase 1 for lung cancer.
  • Kairos Pharma's ENV-105 aims to restore standard therapy effectiveness, offering hope for patients with resistant cancers.
  • Kairos Pharma's ENV-105 targets CD105, a protein driving cancer relapse, potentially changing how we treat drug-resistant tumors.

Impact - Why it Matters

This news matters because it provides investors and the medical community with a timely update on Kairos Pharma's clinical progress for ENV-105, a promising therapy targeting drug resistance in cancer. The presentation at a major investment conference signals potential partnership opportunities and could influence the company's stock performance. For patients, ENV-105 represents hope for more effective treatments against resistant cancers like prostate and lung cancer, addressing a critical unmet need in oncology.

Summary

Kairos Pharma (NYSE American: KAPA) has announced that CEO and Chairman Dr. John Yu will deliver a presentation at the 16th Annual LD Micro Invitational on May 18, 2026, at 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles. During this event, Dr. Yu will provide an update on the company’s clinical program and partnering activities, highlighting the progress of its lead candidate, ENV-105. This antibody targets CD105, a protein identified as a key driver of drug resistance and disease relapse in cancer patients. ENV-105 aims to reverse resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. It is important to note that ENV-105 has not yet been approved as safe or effective by the FDA or any comparable foreign regulator.

Kairos Pharma, based in Los Angeles, is at the forefront of oncology therapeutics, using structural biology to overcome drug resistance and immune suppression. The company's focus on CD105 represents a novel approach to tackling therapy resistance, a major challenge in oncology. The presentation at the LD Micro Invitational offers investors and industry stakeholders a chance to hear directly from leadership about the company's strategic direction and clinical milestones. For the latest news and updates regarding KAPA, investors can visit the company’s newsroom at https://ibn.fm/KAPA.

This press release was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire provides advanced wire-grade press release syndication for private and public companies, offering access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution via IBN to millions of followers, and tailored corporate communications solutions. With a seasoned team of journalists and writers, InvestorWire helps clients cut through information overload to achieve unparalleled recognition and brand awareness. For more information, visit https://www.InvestorWire.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma CEO to Present at LD Micro Invitational

blockchain registration record for this content.